Cargando…
Zafirlukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, Reduces the Effect of Advanced Glycation End-Products in Rat Renal Mesangial Cells In Vitro
BACKGROUND: Zafirlukast is an antagonist of cysteinyl leukotriene receptor 1 (CysLTR1). Advanced glycation end-products (AGEs) are formed by the glycation of lipids and proteins in hyperglycemia, including diabetes mellitus. Zafirlukast has not previously been studied in diabetic nephropathy. This s...
Autores principales: | Yan, Liping, Sun, Ani, Xu, Xinwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880630/ https://www.ncbi.nlm.nih.gov/pubmed/31745068 http://dx.doi.org/10.12659/MSM.918187 |
Ejemplares similares
-
Salidroside Protects Against Advanced Glycation End Products-Induced Vascular Endothelial Dysfunction
por: Zhang, Peng, et al.
Publicado: (2018) -
Trifluoperazine Inhibits Mesangial Cell Proliferation by Arresting Cell Cycle-Dependent Mechanisms
por: Wang, Baodong, et al.
Publicado: (2017) -
Montelukast: More than a Cysteinyl Leukotriene Receptor Antagonist?
por: Tintinger, Gregory R., et al.
Publicado: (2010) -
Cysteinyl Leukotriene Pathway and Cancer
por: Tsai, Ming-Ju, et al.
Publicado: (2021) -
Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients
por: Tsai, Ming-Ju, et al.
Publicado: (2016)